When do you take cold fx

Close Local your local region National. Search Submit search Quick Search. Comments Close comments menu. Video link. Close X. Click to scroll back to top of the page Back to top.

By Carmen Chai Global News. Posted December 17, am. Updated December 17, pm. Smaller font Descrease article font size - A. But taking a closer look at the raw data paints a different picture. First, the researchers did not actually test participants to confirm if the coughs, sniffles or other symptoms they experienced were the result of a virus.

Instead, they asked participants to record the severity of symptoms on a four-point scale, referred to as Jackson criteria. This is important.

Without confirming whether people were actually suffering from a respiratory illness, it's a leap to draw conclusions about the effectiveness of the remedy being studied. At least, that is the perspective offered by Dr.

According to Dr. McElhaney, people who report having a stuffy nose or sniffles could be suffering from hay fever or another ailment unrelated to colds or the flu. Even if you put stock in self reports, Cold-FX didn't score well. The results of the CMAJ study show that over four months, the mean number of colds experienced by the group taking the placebo was 0.

In those taking Cold-FX, it was 0. A difference of 0. Does that seem like a compelling reason to shell out a few hundred bucks and take pills daily for months? A more recent study led by Dr. McElhaney forms the basis of the new bold claim that Cold-FX and the flu shot work better together. The study focused on flu-vaccinated seniors over age Researchers had them take either a placebo, or milligrams of Cold-FX a day for six months. In this case, the researchers actually tested participants for the flu or other viruses in addition to using the self-reported symptom scorecards.

In the end, there was no meaningful difference between the number of viruses suffered by the placebo or treatment groups. The researchers concluded "the treatments had no significant effects on the number, severity, or duration of lab-confirmed clinical URIs [upper respiratory infections]. McElhaney said the low numbers of people suffering from lab-confirmed infections that year made it impossible for them to draw any conclusions about the impact of Cold-FX. Outcome measures: Subjects recorded the incidence and duration of respiratory symptoms during the study.

They also recorded the incidence of adverse events during the study. Results: The frequency and duration of ARI during the first two months of the study was found to be similar in the two groups.